stockrow
Friday 6 November 2026
Export MOBI’s income statement to Excel — free account
Mobia Medical, Inc
MOBI Healthcare Medical Devices
Mobia Medical, Inc’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 104.8% from fiscal 2024.
- Revenue
- +175.9%
- EPS
- +96.0%
- Free cash flow
- −18.0%
Quarter to September 2026, against a year earlier
11.12
0.16
−1.42%
Follow MOBI
Alert me
| Dec '24 | Dec '25 | |
|---|---|---|
P/E ratio |
0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(19.74) | (10.64) |
P/FCF ratio |
0.00 | 0.00 |
Beneish M-Score |
— | (1.68) |
P/Operating CF |
(0.61) | (0.61) |
P/B ratio |
0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 |
EV/Operating CF |
(0.04) | (0.04) |
EV/FCF |
(0.04) | (0.04) |
Quick Ratio |
3.80 | 3.73 |
Current Ratio |
4.61 | 4.54 |
Net Debt/EBITDA |
0.31 | 0.57 |
Debt/Assets |
32.11% | 14.81% |
Debt/Equity |
(0.07) | 0.25 |
Asset Turnover |
0.00 | 0.91 |
Operating CF/Net income |
0.99 | 0.98 |
Capex/Depreciation |
(0.27) | (1.94) |
Interest Coverage |
(24.99) | (47.93) |
| 0.00% | 36.21% | |
| 0.00% | (132.40%) | |
ROIC |
0.00% | (1,140.09%) |
Return on Tangible Assets |
(144.43%) | (126.28%) |
Average Days of Receivables |
65.94 | 50.52 |
Research and Development Expense of Revenue |
27.12% | 20.33% |
Selling, General and Administrative Expense of Revenue |
207.38% | 205.45% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
4.85% | 4.52% |
Graham Net Nets |
0.94 | 0.94 |
Graham Number |
0.00 | 0.00 |
Earnings Yield |
(341.88%) | (341.88%) |
Free Cash Flow Yield |
(783.22%) | (783.22%) |
Revenue per Share |
27.21 | 37.74 |
Operating CF per Share |
(42.29) | (53.82) |
Capex per Share |
(0.07) | (0.43) |
Free Cash Flow per Share |
(42.36) | (54.25) |
Cash per Share |
25.43 | 39.56 |
Shareholders Equity per Share |
(184.41) | 34.16 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(184.41) | 34.16 |
Free Cash Flow |
(24.36) | (46.06) |
Working Capital |
16.58 | 36.15 |
Capital Expenditures |
(0.04) | (0.36) |
Net Current Asset Value |
(106.95) | 27.21 |
EV/EBIT |
0.00 | 0.00 |
Capex to Sales |
0.00 | 0.01 |
Price to Operating Income |
0.00 | 0.00 |
| Other line items | ||
Depreciation/Fixed assets |
0.33 | 0.28 |
Cash ROIC |
28.88% | (66.07%) |
Accounts Receivable Turnover |
0.00 | 8.83 |
Accounts Payable Turnover |
0.00 | 3.61 |
Inventory Turnover |
0.00 | 1.37 |
Average Days of Payables |
130.23 | 133.76 |
Days of Inventory on Hand |
391.98 | 328.34 |
Average Receivables |
— | 3.63 |
Average Payables |
— | 1.68 |
Average Inventory |
— | 4.44 |
Average Assets |
— | 35.12 |
Average Common Equity |
— | (128.40) |
Columns are period end dates · fundamentals updated 5 Nov 2026